Unitaid Announces $6.9 Million Funding for TLC-ART to Transform Current HIV Drugs into Long-Acting Injectables for Worldwide Use

Unitaid, a hosted funding partner of the WHO, announced investment in the TLC-ART drug-combination nanoparticle platform technology to transform current short-acting HIV drug combinations into long-acting medicines to simplify treatment for people living with HIV. Through the four-year GLAD (Global Long-Acting Drug) project, Unitaid has committed $6.9 million to leverage UW technological innovation and know-how in developing longer-lasting HIV combination medicines for world-wide access.

For more information about the Unitaid announcement please follow this link:

https://unitaid.org/news-blog/unitaid-invests-in-long-acting-medicines-to-simplify-treatment-and-prevention-for-hiv-tb-malaria-and-hcv/#en